Find a Clinical Trial
Filter
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Breast cancer, Locally advanced and metastatic breast cancer
All genders
Recruiting now
Cancer Center
Evaluation of BE1116 (4F-PCC) in patients with traumatic injury and confirmed or suspected acute major bleeding to improve survival
Trauma
All genders
Recruiting now
Department of Surgery, Division of Trauma
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Breast Cancer Database
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
All genders
Recruiting now
Cancer Center
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast cancer
All genders
Recruiting now
Cancer Center
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Period Kits
Autism, Menstruation
All genders
Recruiting now
Department of Obstetrics + Gynecology
HER2 Negative Breast Cancer
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center